Versant Capital Management’s Novavax NVAX Stock Holding History

Versant Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.41K	Sell	680 -575	-46%	-$5.15K	﹤0.01%	2373
2026 Q1	$10.2K	Buy	1,255 +586	+88%	+$5.31K	﹤0.01%	2135
2025 Q4	$4.5K	Sell	669 -158	-19%	-$1.19K	﹤0.01%	2289
2025 Q3	$7.17K	Hold	827	–	–	﹤0.01%	2069
2025 Q2	$5.21K	Buy	+827	New	+$5.48K	﹤0.01%	2135
2022 Q1	–	Sell	-2	Closed	–	–	1571
2021 Q4	$0	Sell	2 -5	-71%	-$859	﹤0.01%	1542
2021 Q3	$1K	Buy	7 +2	+40%	+$441	﹤0.01%	1328
2021 Q2	$1K	Buy	5 +2	+67%	+$366	﹤0.01%	1330
2021 Q1	$1K	Buy	+3	New	+$598	﹤0.01%	1403

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Versant Capital Management's NVAX Position: Q2 2026 in Review

Versant Capital Management reduced its Novavax (NVAX) stake by 46% in Q2 2026, selling an estimated $5.15K and leaving 680 shares worth $6.41K. The position accounts for ﹤0.01% of the portfolio, ranked #2373.

Versant Capital Management first reported a position in NVAX in Q1 2021 and has held it in 9 quarters since. The position peaked at $10.2K in Q1 2026. 266 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

Versant Capital Management held 680 shares of Novavax worth $6.41K as of Q2 2026.
Versant Capital Management sold 575 Novavax shares in Q2 2026, an estimated $5.15K.
Novavax made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2373 holding.
Versant Capital Management first reported a position in Novavax in Q1 2021 and has held it in 9 quarters since.
Versant Capital Management's Novavax position peaked at $10.2K in Q1 2026.
266 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.